Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Tandem Diabetes Care Inc (NASDAQ: TNDM) closed the day trading at $32.62 down -2.54% from the previous closing price of $33.47. In other words, the price has decreased by -$2.54 from its previous closing price. On the day, 1.07 million shares were traded.
Ratios:
For a better understanding of TNDM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.32 and its Current Ratio is at 2.90. In the meantime, Its Debt-to-Equity ratio is 2.00 whereas as Long-Term Debt/Eq ratio is at 1.76.
On November 06, 2024, Bernstein started tracking the stock assigning a Outperform rating and target price of $42.
On October 04, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $46.Goldman initiated its Neutral rating on October 04, 2024, with a $46 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 21 ’24 when BLICKENSTAFF KIM D sold 30,000 shares for $31.38 per share. The transaction valued at 941,400 led to the insider holds 165,190 shares of the business.
BLICKENSTAFF KIM D sold 10,000 shares of TNDM for $300,000 on Nov 20 ’24. The Director now owns 195,190 shares after completing the transaction at $30.00 per share. On Nov 21 ’24, another insider, BLICKENSTAFF KIM D, who serves as the Board of Directors, Chair Emer of the company, bought 30,000 shares for $30.00 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.51 while its Price-to-Book (P/B) ratio in mrq is 9.01.
Stock Price History:
Over the past 52 weeks, TNDM has reached a high of $53.69, while it has fallen to a 52-week low of $22.03. The 50-Day Moving Average of the stock is -7.33%, while the 200-Day Moving Average is calculated to be -17.13%.
Shares Statistics:
A total of 65.65M shares are outstanding, with a floating share count of 65.17M. Insiders hold about 0.77% of the company’s shares, while institutions hold 113.29% stake in the company.
Earnings Estimates
The current rating of Tandem Diabetes Care Inc (TNDM) is the result of assessments by 17.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.19 and low estimates of -$0.59.
Analysts are recommending an EPS of between -$1.52 and -$1.86 for the fiscal current year, implying an average EPS of -$1.72. EPS for the following year is -$1.19, with 19.0 analysts recommending between -$0.72 and -$1.51.
Revenue Estimates
18 analysts predict $251.39M in revenue for the current quarter. It ranges from a high estimate of $281M to a low estimate of $244.8M. As of the current estimate, Tandem Diabetes Care Inc’s year-ago sales were $196.8MFor the next quarter, 18 analysts are estimating revenue of $220.7M. There is a high estimate of $230M for the next quarter, whereas the lowest estimate is $213.88M.
A total of 20 analysts have provided revenue estimates for TNDM’s current fiscal year. The highest revenue estimate was $938.6M, while the lowest revenue estimate was $903.3M, resulting in an average revenue estimate of $909.33M. In the same quarter a year ago, actual revenue was $747.72MBased on 21 analysts’ estimates, the company’s revenue will be $1.01B in the next fiscal year. The high estimate is $1.03B and the low estimate is $984.2M.
